Related Experiment Video
Updated: Nov 1, 2025
Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021
In vivo CD40 Silencing by siRNA Infusion in Rodents and Evaluation by Kidney Immunostaining
Miguel Hueso1, Adrián Mallén2, Elia Ripoll2
1Department of Nephrology, Hospital Universitari Bellvitge, and Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.
Abstract:
The co-stimulatory molecule CD40 and its ligand CD40L play a key role in the regulation of immunological processes and are involved in the pathophysiology of autoimmune and inflammatory diseases. Inhibition of the CD40-CD40L axis is a promising therapy, and a number of strategies and techniques have been designed to hinder its functionality. Our group has broad experience in silencing CD40 using RNAi technology, and here we summarize protocols for the systemic administration of a specific anti-CD40 siRNA in different rodents models, in addition to the subsequent quantification of CD40 expression in murine kidneys by immunostaining. The use of RNAi technology with specific siRNAs to silence genes is becoming an essential method to investigate gene functions and is rapidly emerging as a therapeutic tool. Graphic abstract: CD40 siRNA mechanism.
Insights
This study details protocols for using small interfering RNA (siRNA) to silence CD40, a key molecule in immune responses. Systemic administration in rodents and kidney CD40 expression analysis are described for potential autoimmune disease therapies.
Area of Science:
- Immunology
- Molecular Biology
- Pharmacology
Background:
- The CD40-CD40L axis is crucial for immune regulation and implicated in autoimmune/inflammatory diseases.
- Inhibiting the CD40-CD40L pathway presents a promising therapeutic strategy.
- RNA interference (RNAi) technology offers a method for gene silencing and therapeutic development.
Purpose of the Study:
- To summarize protocols for systemic administration of anti-CD40 siRNA in rodent models.
- To describe the quantification of CD40 expression in murine kidneys post-siRNA treatment.
- To highlight the utility of RNAi for investigating gene function and therapeutic applications.
Main Methods:
- Systemic administration of a specific anti-CD40 siRNA in rodent models.
- Immunohistochemical staining to quantify CD40 expression in murine kidneys.
- Utilizing RNAi technology for targeted gene silencing.
Main Results:
- Protocols for effective systemic delivery of anti-CD40 siRNA were established.
- CD40 expression levels in murine kidneys were successfully quantified post-treatment.
- Demonstrated feasibility of using siRNA for CD40 silencing in vivo.
Conclusions:
- Systemic administration of anti-CD40 siRNA is a viable method for targeting CD40.
- RNAi technology serves as a powerful tool for both research and therapeutic interventions in immune-related diseases.
- This approach holds potential for treating autoimmune and inflammatory conditions.
